Leitliniengerechte Diagnostik und Therapie von Gliomen

Zusammenfassung

Aufgrund der problematischen Prognose der Gliome ist die Behandlung dieser Tumoren komplex und bedarf der Mitwirkung aller in der Neuroonkologie tätigen Fächer. In jüngeren Jahren konnten erfreulicherweise viele Daten generiert werden, welche zu neuen therapeutischen Standards geführt haben, wie der nach radiologischen Kriterien vollständigen Resektion von Glioblastomen und der Radiochemotherapie mit Temozolomid. Auch die Diagnostik wurde durch die metabolische Bildgebung und die Möglichkeiten der Molekulargenetik wesentlich aussagekräftiger. Der folgende Artikel soll die wichtigsten dieser Daten und Standards vermitteln, welche auch in einer von allen relevanten Fachgesellschaften anerkannten Leitlinie zusammengefasst sind.

• Literatur

• 1 Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109
• 2 Kreth FW, Faist M, Grau S et al. Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer 2006; 106: 1372-1381
• 3 Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003
• 4 Hartmann C, Hentschel B, Tatagiba M et al. Molecular markers in low-grade gliomas: predictive or prognostic?. Clin Cancer Res 2011; 17: 4588-4599
• 5 Wick W, Hartmann C, Engel C et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009; 27: 5874-5880
• 6 Erdem-Eraslan L, Gravendeel LA, de Rooi J et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 2013; 31: 328-336
• 7 Sanson M, Marie Y, Paris S et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 2009; 27: 4150-4154
• 8 Juratli TA, Kirsch M, Geiger K et al. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas. J Neurooncol 2012; 110: 325-333
• 9 Rachinger W, Goetz C, Pöpperl G et al. Positron emission tomography with O- (2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 2005; 57: 505-511
• 10 Brandsma D, Stalpers L, Taal W et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 2008; 9: 453-461
• 11 Pöpperl G, Kreth FW, Mehrkens JH et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging 2007; 34: 1933-1942
• 12 Rapp M, Heinzel A, Galldiks N et al. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 2013; 54: 229-235
• 13 Rachinger W, Grau S, Holtmannspötter M et al. Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only. J Neurol Neurosurg Psychiatry 2009; 80: 1134-1139
• 14 Stummer W, Pichlmeier U, Meinel T et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401
• 15 Grosu AL, Weber WA, Riedel E et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 64-74
• 16 Ruge MI, Kickingereder P, Simon T et al. Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. J Neurooncol 2012; 109: 273-283
• 17 Ruge MI, Simon T, Suchorska B et al. Stereotactic brachytherapy with 125Iodine seeds (SBT) for the treatment of inoperable low-grade gliomas in children: long-term outcome of 147 patients. J Clin Oncol 2011; 29: 4151-4159 [Epub 2011, Oct 3]
• 18 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996
• 19 Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13: 7077-7015
• 20 Wick W, Steinbach JP, Küker WM et al. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62: 2113-2115
• 21 Brandes AA, Tosoni A, Cavallo G et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006; 95: 1155-1160
• 22 Westphal M, Hilt DC, Bortey E et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003; 5: 79-88
• 23 Weller M, Gorlia T, Cairncross JG et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 2011; 77: 1156-1164
• 24 Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89: 640-646
• 25 Klein M. Health-related quality of life aspects in patients with low-grade glioma. Adv Tech Stand Neurosurg 2010; 35: 213-235
• 26 Glas M, Bähr O, Felsberg J et al. NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011; 70: 445-453
• 27 Eroes CA, Zausinger S, Kreth FW et al. Intramedullary low grade astrocytoma and ependymoma. Surgical results and predicting factors for clinical outcome. Acta Neurochir (Wien) 2010; 152: 611-618